Sellas Life Sciences Group Inc. SLS
$7.72
▲ +1.03% 24H
About
Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy that targets the Wilms tumor 1 (WT1) protein and addresses hematologic maligna…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees15
TickerSLS
Statistics
Market Cap$1.40B
Revenue (TTM)—
Net Income-$26.9M
Net Margin—
EPS$-0.25
P/E-31.24
P/S—
P/B13.09
EV/EBITDA-47.24
ROE-43.6%
Dividend Yield—
Price$7.72
Data: Twelve Data · Revenue = mcap / P/S